Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Zacks Equity Research shares Hims & Hers Health HIMS as the Bull of the Day and AST SpaceMobile ASTS as the Bear of the D ...

Studies have found that patients lose around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo Nordisk's A/S (NYSE: NVO) Wegovy. Hims will ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.